CoRSeqV3-C: a novel HIV-1 subtype C specific V3 sequence based coreceptor usage prediction algorithm
Background The majority of HIV-1 subjects worldwide are infected with HIV-1 subtype C (C-HIV). Although C-HIV predominates in developing regions of the world such as Southern Africa and Central Asia, C-HIV is also spreading rapidly in countries with more developed economies and health care systems,...
Saved in:
| Published in | Retrovirology Vol. 10; no. 1; p. 24 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
27.02.2013
BioMed Central Ltd Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1742-4690 1742-4690 |
| DOI | 10.1186/1742-4690-10-24 |
Cover
| Abstract | Background
The majority of HIV-1 subjects worldwide are infected with HIV-1 subtype C (C-HIV). Although C-HIV predominates in developing regions of the world such as Southern Africa and Central Asia, C-HIV is also spreading rapidly in countries with more developed economies and health care systems, whose populations are more likely to have access to wider treatment options, including the CCR5 antagonist maraviroc (MVC). The ability to reliably determine C-HIV coreceptor usage is therefore becoming increasingly more important.
In silico
V3 sequence based coreceptor usage prediction algorithms are a relatively rapid and cost effective method for determining HIV-1 coreceptor specificity. In this study, we elucidated the V3 sequence determinants of C-HIV coreceptor usage, and used this knowledge to develop and validate a novel, user friendly, and highly sensitive C-HIV specific coreceptor usage prediction algorithm.
Results
We characterized every phenotypically-verified C-HIV gp120 V3 sequence available in the Los Alamos HIV Database. Sequence analyses revealed that compared to R5 C-HIV V3 sequences, CXCR4-using C-HIV V3 sequences have significantly greater amino acid variability, increased net charge, increased amino acid length, increased frequency of insertions and substitutions within the GPGQ crown motif, and reduced frequency of glycosylation sites. Based on these findings, we developed a novel C-HIV specific coreceptor usage prediction algorithm (CoRSeq
V3-C
), which we show has superior sensitivity for determining CXCR4 usage by C-HIV strains compared to all other available algorithms and prediction rules, including Geno2pheno
[coreceptor]
and WebPSSM
SINSI
-C, which has been designed specifically for C-HIV.
Conclusions
CoRSeq
V3-C
is now openly available for public use at
http://www.burnet.edu.au/coreceptor
. Our results show that CoRSeq
V3-C
is the most sensitive V3 sequence based algorithm presently available for predicting CXCR4 usage of C-HIV strains, without compromising specificity. CoRSeq
V3-C
may be potentially useful for assisting clinicians to decide the best treatment options for patients with C-HIV infection, and will be helpful for basic studies of C-HIV pathogenesis. |
|---|---|
| AbstractList | Doc number: 24 Abstract Background: The majority of HIV-1 subjects worldwide are infected with HIV-1 subtype C (C-HIV). Although C-HIV predominates in developing regions of the world such as Southern Africa and Central Asia, C-HIV is also spreading rapidly in countries with more developed economies and health care systems, whose populations are more likely to have access to wider treatment options, including the CCR5 antagonist maraviroc (MVC). The ability to reliably determine C-HIV coreceptor usage is therefore becoming increasingly more important. In silico V3 sequence based coreceptor usage prediction algorithms are a relatively rapid and cost effective method for determining HIV-1 coreceptor specificity. In this study, we elucidated the V3 sequence determinants of C-HIV coreceptor usage, and used this knowledge to develop and validate a novel, user friendly, and highly sensitive C-HIV specific coreceptor usage prediction algorithm. Results: We characterized every phenotypically-verified C-HIV gp120 V3 sequence available in the Los Alamos HIV Database. Sequence analyses revealed that compared to R5 C-HIV V3 sequences, CXCR4-using C-HIV V3 sequences have significantly greater amino acid variability, increased net charge, increased amino acid length, increased frequency of insertions and substitutions within the GPGQ crown motif, and reduced frequency of glycosylation sites. Based on these findings, we developed a novel C-HIV specific coreceptor usage prediction algorithm (CoRSeqV3-C ), which we show has superior sensitivity for determining CXCR4 usage by C-HIV strains compared to all other available algorithms and prediction rules, including Geno2pheno[coreceptor] and WebPSSMSINSI -C, which has been designed specifically for C-HIV. Conclusions: CoRSeqV3-C is now openly available for public use at http://www.burnet.edu.au/coreceptor . Our results show that CoRSeqV3-C is the most sensitive V3 sequence based algorithm presently available for predicting CXCR4 usage of C-HIV strains, without compromising specificity. CoRSeqV3-C may be potentially useful for assisting clinicians to decide the best treatment options for patients with C-HIV infection, and will be helpful for basic studies of C-HIV pathogenesis. Background The majority of HIV-1 subjects worldwide are infected with HIV-1 subtype C (C-HIV). Although C-HIV predominates in developing regions of the world such as Southern Africa and Central Asia, C-HIV is also spreading rapidly in countries with more developed economies and health care systems, whose populations are more likely to have access to wider treatment options, including the CCR5 antagonist maraviroc (MVC). The ability to reliably determine C-HIV coreceptor usage is therefore becoming increasingly more important. In silico V3 sequence based coreceptor usage prediction algorithms are a relatively rapid and cost effective method for determining HIV-1 coreceptor specificity. In this study, we elucidated the V3 sequence determinants of C-HIV coreceptor usage, and used this knowledge to develop and validate a novel, user friendly, and highly sensitive C-HIV specific coreceptor usage prediction algorithm. Results We characterized every phenotypically-verified C-HIV gp120 V3 sequence available in the Los Alamos HIV Database. Sequence analyses revealed that compared to R5 C-HIV V3 sequences, CXCR4-using C-HIV V3 sequences have significantly greater amino acid variability, increased net charge, increased amino acid length, increased frequency of insertions and substitutions within the GPGQ crown motif, and reduced frequency of glycosylation sites. Based on these findings, we developed a novel C-HIV specific coreceptor usage prediction algorithm (CoRSeq.sub.V3-C), which we show has superior sensitivity for determining CXCR4 usage by C-HIV strains compared to all other available algorithms and prediction rules, including Geno2pheno.sub.[coreceptor] and WebPSSM.sub.SINSI-C, which has been designed specifically for C-HIV. Conclusions CoRSeq.sub.V3-C is now openly available for public use at Keywords: HIV-1, subtype C, gp120, V3, CCR5, CXCR4, Coreceptor, Prediction algorithm The majority of HIV-1 subjects worldwide are infected with HIV-1 subtype C (C-HIV). Although C-HIV predominates in developing regions of the world such as Southern Africa and Central Asia, C-HIV is also spreading rapidly in countries with more developed economies and health care systems, whose populations are more likely to have access to wider treatment options, including the CCR5 antagonist maraviroc (MVC). The ability to reliably determine C-HIV coreceptor usage is therefore becoming increasingly more important. In silico V3 sequence based coreceptor usage prediction algorithms are a relatively rapid and cost effective method for determining HIV-1 coreceptor specificity. In this study, we elucidated the V3 sequence determinants of C-HIV coreceptor usage, and used this knowledge to develop and validate a novel, user friendly, and highly sensitive C-HIV specific coreceptor usage prediction algorithm.BACKGROUNDThe majority of HIV-1 subjects worldwide are infected with HIV-1 subtype C (C-HIV). Although C-HIV predominates in developing regions of the world such as Southern Africa and Central Asia, C-HIV is also spreading rapidly in countries with more developed economies and health care systems, whose populations are more likely to have access to wider treatment options, including the CCR5 antagonist maraviroc (MVC). The ability to reliably determine C-HIV coreceptor usage is therefore becoming increasingly more important. In silico V3 sequence based coreceptor usage prediction algorithms are a relatively rapid and cost effective method for determining HIV-1 coreceptor specificity. In this study, we elucidated the V3 sequence determinants of C-HIV coreceptor usage, and used this knowledge to develop and validate a novel, user friendly, and highly sensitive C-HIV specific coreceptor usage prediction algorithm.We characterized every phenotypically-verified C-HIV gp120 V3 sequence available in the Los Alamos HIV Database. Sequence analyses revealed that compared to R5 C-HIV V3 sequences, CXCR4-using C-HIV V3 sequences have significantly greater amino acid variability, increased net charge, increased amino acid length, increased frequency of insertions and substitutions within the GPGQ crown motif, and reduced frequency of glycosylation sites. Based on these findings, we developed a novel C-HIV specific coreceptor usage prediction algorithm (CoRSeqV3-C), which we show has superior sensitivity for determining CXCR4 usage by C-HIV strains compared to all other available algorithms and prediction rules, including Geno2pheno[coreceptor] and WebPSSMSINSI-C, which has been designed specifically for C-HIV.RESULTSWe characterized every phenotypically-verified C-HIV gp120 V3 sequence available in the Los Alamos HIV Database. Sequence analyses revealed that compared to R5 C-HIV V3 sequences, CXCR4-using C-HIV V3 sequences have significantly greater amino acid variability, increased net charge, increased amino acid length, increased frequency of insertions and substitutions within the GPGQ crown motif, and reduced frequency of glycosylation sites. Based on these findings, we developed a novel C-HIV specific coreceptor usage prediction algorithm (CoRSeqV3-C), which we show has superior sensitivity for determining CXCR4 usage by C-HIV strains compared to all other available algorithms and prediction rules, including Geno2pheno[coreceptor] and WebPSSMSINSI-C, which has been designed specifically for C-HIV.CoRSeqV3-C is now openly available for public use at http://www.burnet.edu.au/coreceptor. Our results show that CoRSeqV3-C is the most sensitive V3 sequence based algorithm presently available for predicting CXCR4 usage of C-HIV strains, without compromising specificity. CoRSeqV3-C may be potentially useful for assisting clinicians to decide the best treatment options for patients with C-HIV infection, and will be helpful for basic studies of C-HIV pathogenesis.CONCLUSIONSCoRSeqV3-C is now openly available for public use at http://www.burnet.edu.au/coreceptor. Our results show that CoRSeqV3-C is the most sensitive V3 sequence based algorithm presently available for predicting CXCR4 usage of C-HIV strains, without compromising specificity. CoRSeqV3-C may be potentially useful for assisting clinicians to decide the best treatment options for patients with C-HIV infection, and will be helpful for basic studies of C-HIV pathogenesis. The majority of HIV-1 subjects worldwide are infected with HIV-1 subtype C (C-HIV). Although C-HIV predominates in developing regions of the world such as Southern Africa and Central Asia, C-HIV is also spreading rapidly in countries with more developed economies and health care systems, whose populations are more likely to have access to wider treatment options, including the CCR5 antagonist maraviroc (MVC). The ability to reliably determine C-HIV coreceptor usage is therefore becoming increasingly more important. In silico V3 sequence based coreceptor usage prediction algorithms are a relatively rapid and cost effective method for determining HIV-1 coreceptor specificity. In this study, we elucidated the V3 sequence determinants of C-HIV coreceptor usage, and used this knowledge to develop and validate a novel, user friendly, and highly sensitive C-HIV specific coreceptor usage prediction algorithm. We characterized every phenotypically-verified C-HIV gp120 V3 sequence available in the Los Alamos HIV Database. Sequence analyses revealed that compared to R5 C-HIV V3 sequences, CXCR4-using C-HIV V3 sequences have significantly greater amino acid variability, increased net charge, increased amino acid length, increased frequency of insertions and substitutions within the GPGQ crown motif, and reduced frequency of glycosylation sites. Based on these findings, we developed a novel C-HIV specific coreceptor usage prediction algorithm (CoRSeqV3-C), which we show has superior sensitivity for determining CXCR4 usage by C-HIV strains compared to all other available algorithms and prediction rules, including Geno2pheno[coreceptor] and WebPSSMSINSI-C, which has been designed specifically for C-HIV. CoRSeqV3-C is now openly available for public use at http://www.burnet.edu.au/coreceptor. Our results show that CoRSeqV3-C is the most sensitive V3 sequence based algorithm presently available for predicting CXCR4 usage of C-HIV strains, without compromising specificity. CoRSeqV3-C may be potentially useful for assisting clinicians to decide the best treatment options for patients with C-HIV infection, and will be helpful for basic studies of C-HIV pathogenesis. Background The majority of HIV-1 subjects worldwide are infected with HIV-1 subtype C (C-HIV). Although C-HIV predominates in developing regions of the world such as Southern Africa and Central Asia, C-HIV is also spreading rapidly in countries with more developed economies and health care systems, whose populations are more likely to have access to wider treatment options, including the CCR5 antagonist maraviroc (MVC). The ability to reliably determine C-HIV coreceptor usage is therefore becoming increasingly more important. In silico V3 sequence based coreceptor usage prediction algorithms are a relatively rapid and cost effective method for determining HIV-1 coreceptor specificity. In this study, we elucidated the V3 sequence determinants of C-HIV coreceptor usage, and used this knowledge to develop and validate a novel, user friendly, and highly sensitive C-HIV specific coreceptor usage prediction algorithm. Results We characterized every phenotypically-verified C-HIV gp120 V3 sequence available in the Los Alamos HIV Database. Sequence analyses revealed that compared to R5 C-HIV V3 sequences, CXCR4-using C-HIV V3 sequences have significantly greater amino acid variability, increased net charge, increased amino acid length, increased frequency of insertions and substitutions within the GPGQ crown motif, and reduced frequency of glycosylation sites. Based on these findings, we developed a novel C-HIV specific coreceptor usage prediction algorithm (CoRSeq V3-C ), which we show has superior sensitivity for determining CXCR4 usage by C-HIV strains compared to all other available algorithms and prediction rules, including Geno2pheno [coreceptor] and WebPSSM SINSI -C, which has been designed specifically for C-HIV. Conclusions CoRSeq V3-C is now openly available for public use at http://www.burnet.edu.au/coreceptor . Our results show that CoRSeq V3-C is the most sensitive V3 sequence based algorithm presently available for predicting CXCR4 usage of C-HIV strains, without compromising specificity. CoRSeq V3-C may be potentially useful for assisting clinicians to decide the best treatment options for patients with C-HIV infection, and will be helpful for basic studies of C-HIV pathogenesis. The majority of HIV-1 subjects worldwide are infected with HIV-1 subtype C (C-HIV). Although C-HIV predominates in developing regions of the world such as Southern Africa and Central Asia, C-HIV is also spreading rapidly in countries with more developed economies and health care systems, whose populations are more likely to have access to wider treatment options, including the CCR5 antagonist maraviroc (MVC). The ability to reliably determine C-HIV coreceptor usage is therefore becoming increasingly more important. In silico V3 sequence based coreceptor usage prediction algorithms are a relatively rapid and cost effective method for determining HIV-1 coreceptor specificity. In this study, we elucidated the V3 sequence determinants of C-HIV coreceptor usage, and used this knowledge to develop and validate a novel, user friendly, and highly sensitive C-HIV specific coreceptor usage prediction algorithm. We characterized every phenotypically-verified C-HIV gp120 V3 sequence available in the Los Alamos HIV Database. Sequence analyses revealed that compared to R5 C-HIV V3 sequences, CXCR4-using C-HIV V3 sequences have significantly greater amino acid variability, increased net charge, increased amino acid length, increased frequency of insertions and substitutions within the GPGQ crown motif, and reduced frequency of glycosylation sites. Based on these findings, we developed a novel C-HIV specific coreceptor usage prediction algorithm (CoRSeq.sub.V3-C), which we show has superior sensitivity for determining CXCR4 usage by C-HIV strains compared to all other available algorithms and prediction rules, including Geno2pheno.sub.[coreceptor] and WebPSSM.sub.SINSI-C, which has been designed specifically for C-HIV. CoRSeq.sub.V3-C is now openly available for public use at http://www.burnet.edu.au/coreceptor. Our results show that CoRSeq.sub.V3-C is the most sensitive V3 sequence based algorithm presently available for predicting CXCR4 usage of C-HIV strains, without compromising specificity. CoRSeq.sub.V3-C may be potentially useful for assisting clinicians to decide the best treatment options for patients with C-HIV infection, and will be helpful for basic studies of C-HIV pathogenesis. |
| ArticleNumber | 24 |
| Audience | Academic |
| Author | Cashin, Kieran Gray, Lachlan R Churchill, Melissa J Gorry, Paul R Sterjovski, Jasminka Jakobsen, Martin R |
| AuthorAffiliation | 7 Present address: Department of Biomedicine, Aarhus University, Aarhus, Denmark 3 Departments of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, Australia 6 Departments of Infectious Diseases, Monash University, Melbourne, VIC, Australia 5 Departments of Medicine, Monash University, Melbourne, VIC, Australia 1 Center for Virology, Burnet Institute, 85 Commercial Rd, Melbourne 3004VIC, Australia 2 Department of Microbiology and Immunology, University of Melbourne, Parkville, VIC, Australia 4 Departments of Microbiology, Monash University, Melbourne, VIC, Australia |
| AuthorAffiliation_xml | – name: 4 Departments of Microbiology, Monash University, Melbourne, VIC, Australia – name: 3 Departments of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, Australia – name: 7 Present address: Department of Biomedicine, Aarhus University, Aarhus, Denmark – name: 1 Center for Virology, Burnet Institute, 85 Commercial Rd, Melbourne 3004VIC, Australia – name: 6 Departments of Infectious Diseases, Monash University, Melbourne, VIC, Australia – name: 2 Department of Microbiology and Immunology, University of Melbourne, Parkville, VIC, Australia – name: 5 Departments of Medicine, Monash University, Melbourne, VIC, Australia |
| Author_xml | – sequence: 1 givenname: Kieran surname: Cashin fullname: Cashin, Kieran organization: Center for Virology, Burnet Institute, Department of Microbiology and Immunology, University of Melbourne – sequence: 2 givenname: Lachlan R surname: Gray fullname: Gray, Lachlan R organization: Center for Virology, Burnet Institute, Departments of Biochemistry and Molecular Biology, Monash University – sequence: 3 givenname: Martin R surname: Jakobsen fullname: Jakobsen, Martin R organization: Center for Virology, Burnet Institute, Department of Biomedicine, Aarhus University – sequence: 4 givenname: Jasminka surname: Sterjovski fullname: Sterjovski, Jasminka organization: Center for Virology, Burnet Institute – sequence: 5 givenname: Melissa J surname: Churchill fullname: Churchill, Melissa J organization: Center for Virology, Burnet Institute, Departments of Microbiology, Monash University, Departments of Medicine, Monash University – sequence: 6 givenname: Paul R surname: Gorry fullname: Gorry, Paul R email: gorry@burnet.edu.au organization: Center for Virology, Burnet Institute, Department of Microbiology and Immunology, University of Melbourne, Departments of Infectious Diseases, Monash University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23446039$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkk1r3DAQhkVJaT7ac29F0EsvTiRL8so9FIJpm0Cg0I-9ClkeOwq25Eh2yv77yuw22YS2FB0kRs870rwzx-jAeQcIvabklFJZnNEVzzNelCSjJMv5M3R0HznYOx-i4xhvCGFUEvkCHeaM84Kw8gg1lf_6DW7XLKveY42dv4MeX1yuM4rjXE-bEXCF4wjGttbgNcMRbmdwBnCtIzTY-AAGxskHPEfdAR4DNNZM1jus-84HO10PL9HzVvcRXu32E_Tj08fv1UV29eXzZXV-lRlRiilbSWgL1lIhiWm51LUAYiCVqWnTGFIXjNclaYWQupCyJiytUvKmrnXeUF6yE0S2eWc36s1P3fdqDHbQYaMoUYtharFELZYskZwnyYetZJzrARoDbgr6Qea1VY9vnL1Wnb9TTJTliomU4N0uQfDJmTipwUYDfa8d-DkqyuhKFpTnLKFvn6A3fg4uObJQRUHyhD5Qne5BWdf69K5ZkqpzwZav85Im6vQPVFoNDNakIWltij8SvNkv9L7C36OQgLMtYIKPMUD7H96JJwpjJ720Pv3F9v_Q7doU0wuug7Dnw18kvwCtXuHI |
| CitedBy_id | crossref_primary_10_1159_000369017 crossref_primary_10_1371_journal_pone_0109771 crossref_primary_10_1089_aid_2013_0267 crossref_primary_10_1089_aid_2015_0318 crossref_primary_10_1186_s12981_015_0066_7 crossref_primary_10_1128_JVI_02222_17 crossref_primary_10_1089_aid_2013_0240 crossref_primary_10_1016_j_jcv_2018_12_007 crossref_primary_10_1371_journal_pcbi_1010355 crossref_primary_10_3390_v6020709 crossref_primary_10_1586_14787210_2013_852469 crossref_primary_10_1177_1176934319831308 crossref_primary_10_1371_journal_pone_0158854 crossref_primary_10_1016_j_compbiolchem_2019_05_006 crossref_primary_10_3389_fmicb_2021_703041 crossref_primary_10_1089_aid_2015_0168 crossref_primary_10_1186_s12977_020_00532_2 crossref_primary_10_2147_JIR_S442106 crossref_primary_10_1371_journal_pone_0065950 crossref_primary_10_1089_aid_2017_0209 crossref_primary_10_1371_journal_pone_0093426 crossref_primary_10_1371_journal_pone_0148974 crossref_primary_10_1016_j_virol_2018_06_005 crossref_primary_10_1038_srep08543 crossref_primary_10_1371_journal_pone_0119879 crossref_primary_10_3389_fimmu_2017_00376 |
| Cites_doi | 10.1128/jvi.66.5.3183-3187.1992 10.1016/j.virusres.2012.06.019 10.1093/cid/cir072 10.1016/S0891-5520(05)70135-5 10.1128/JVI.80.2.750-758.2006 10.3851/IMP1769 10.1086/504693 10.1186/1742-4690-3-52 10.1128/JVI.77.7.4449-4456.2003 10.1128/JVI.76.24.12890-12899.2002 10.1128/JVI.77.24.13376-13388.2003 10.1073/pnas.0606312103 10.1099/vir.0.81510-0 10.1038/381661a0 10.1093/jac/dkr438 10.1006/viro.2002.1760 10.1016/j.virol.2009.07.021 10.1038/nbt1371 10.1097/QAD.0b013e32830ebcd4 10.1201/b13787-282 10.1038/34571 10.1592/phco.29.3.295 10.1016/j.virol.2012.08.013 10.1016/j.virol.2006.07.030 10.1073/pnas.89.20.9434 10.1097/QAI.0b013e3181f63906 10.1126/science.1118398 10.2217/fvl.09.77 10.1128/JVI.76.8.3852-3864.2002 10.1128/jvi.71.9.6305-6314.1997 10.1089/aid.2006.0130 10.1128/JCM.01611-07 10.1016/S0092-8674(00)81313-6 10.1097/01.qai.0000152835.17747.47 10.1089/aid.2007.0304 10.1128/JVI.78.1.524-530.2004 10.1097/QAD.0b013e3282f57f7a 10.1016/j.virol.2005.11.047 10.1084/jem.185.4.621 10.1126/science.1905842 10.1097/QAI.0b013e3181c8413b 10.1126/science.272.5263.872 10.1128/AAC.49.11.4721-4732.2005 10.1128/AAC.00148-10 10.1038/381667a0 10.1097/QAI.0b013e31818ffdff 10.1128/JVI.73.4.2576-2586.1999 10.1128/JVI.78.6.2841-2852.2004 10.1016/j.virol.2012.08.048 10.1128/jvi.66.11.6777-6780.1992 10.1128/JVI.80.10.4698-4704.2006 10.1371/journal.pmed.0030442 10.1089/aid.2006.22.458 |
| ContentType | Journal Article |
| Copyright | Cashin et al; licensee BioMed Central Ltd. 2013 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. COPYRIGHT 2013 BioMed Central Ltd. 2013 Cashin et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright ©2013 Cashin et al; licensee BioMed Central Ltd. 2013 Cashin et al; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: Cashin et al; licensee BioMed Central Ltd. 2013 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: COPYRIGHT 2013 BioMed Central Ltd. – notice: 2013 Cashin et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: Copyright ©2013 Cashin et al; licensee BioMed Central Ltd. 2013 Cashin et al; licensee BioMed Central Ltd. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7U9 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM ADTOC UNPAY |
| DOI | 10.1186/1742-4690-10-24 |
| DatabaseName | SpringerLink - Revues - OpenAccess CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest Central Premium ProQuest One Academic ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1742-4690 |
| EndPage | 24 |
| ExternalDocumentID | 10.1186/1742-4690-10-24 PMC3599735 2916082181 A534690491 23446039 10_1186_1742_4690_10_24 |
| Genre | Evaluation Studies Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- 0R~ 123 29P 2WC 4.4 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS UKHRP WOQ WOW XSB AAYXX CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 7U9 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM 2VQ ADTOC IPNFZ LGEZI LOTEE NADUK NXXTH RIG UNPAY |
| ID | FETCH-LOGICAL-c595t-78ef63f1580cf48ab5e0ce186a1ddc0b634b90f558a688b03030984dbba2d1493 |
| IEDL.DBID | M48 |
| ISSN | 1742-4690 |
| IngestDate | Sun Oct 26 04:00:10 EDT 2025 Tue Sep 30 16:51:27 EDT 2025 Sun Aug 24 04:00:56 EDT 2025 Tue Oct 21 12:46:11 EDT 2025 Mon Oct 20 22:50:01 EDT 2025 Mon Oct 20 17:04:17 EDT 2025 Mon Jul 21 06:04:51 EDT 2025 Thu Apr 24 23:05:41 EDT 2025 Wed Oct 01 04:18:22 EDT 2025 Sat Sep 06 07:25:03 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | HIV-1 subtype C gp120 CXCR4 Coreceptor CCR5 V3 Prediction algorithm |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. cc-by |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c595t-78ef63f1580cf48ab5e0ce186a1ddc0b634b90f558a688b03030984dbba2d1493 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/1742-4690-10-24 |
| PMID | 23446039 |
| PQID | 1316602178 |
| PQPubID | 54665 |
| PageCount | 1 |
| ParticipantIDs | unpaywall_primary_10_1186_1742_4690_10_24 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3599735 proquest_miscellaneous_1317861423 proquest_journals_1316602178 gale_infotracmisc_A534690491 gale_infotracacademiconefile_A534690491 pubmed_primary_23446039 crossref_primary_10_1186_1742_4690_10_24 crossref_citationtrail_10_1186_1742_4690_10_24 springer_journals_10_1186_1742_4690_10_24 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2013-02-27 |
| PublicationDateYYYYMMDD | 2013-02-27 |
| PublicationDate_xml | – month: 02 year: 2013 text: 2013-02-27 day: 27 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Retrovirology |
| PublicationTitleAbbrev | Retrovirology |
| PublicationTitleAlternate | Retrovirology |
| PublicationYear | 2013 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V |
| References | S Dimonte (3409_CR29) 2012; 168 O Rosen (3409_CR40) 2006; 103 T Dragic (3409_CR2) 1996; 381 T Graf (3409_CR16) 2013; 435 P Recordon-Pinson (3409_CR26) 2010; 54 E Delgado (3409_CR31) 2012; 67 MA Jensen (3409_CR24) 2003; 77 G Pollakis (3409_CR46) 2004; 78 A Thielen (3409_CR52) 2011; 16 A Singh (3409_CR32) 2009; 393 I Choge (3409_CR33) 2006; 22 C Garrido (3409_CR28) 2008; 46 P Clevestig (3409_CR48) 2006; 87 GP McCormack (3409_CR34) 2002; 76 TJ Wilkin (3409_CR20) 2011; 52 S Polzer (3409_CR47) 2002; 304 T Cardozo (3409_CR39) 2007; 23 M Coetzer (3409_CR42) 2006; 356 PR Gorry (3409_CR19) 2010 RA Fouchier (3409_CR25) 1992; 66 EN Vergis (3409_CR8) 2000; 14 JS Hunt (3409_CR18) 2009; 29 AA Nabatov (3409_CR49) 2004; 78 T Melby (3409_CR9) 2006; 194 BJ Connell (3409_CR13) 2008; 22 T Ndung’u (3409_CR35) 2006; 347 Y Feng (3409_CR3) 1996; 272 H Choe (3409_CR4) 1996; 85 S Raymond (3409_CR27) 2010; 53 H Deng (3409_CR1) 1996; 381 T Shioda (3409_CR38) 1992; 89 SS Hwang (3409_CR21) 1991; 253 NG Hoffman (3409_CR23) 2002; 76 BJ Doranz (3409_CR44) 1997; 71 CC Huang (3409_CR45) 2005; 310 C Pastore (3409_CR51) 2006; 80 S Raymond (3409_CR30) 2008; 22 MA Jensen (3409_CR37) 2006; 80 K Michler (3409_CR12) 2008; 24 P Dorr (3409_CR17) 2005; 49 NH Lin (3409_CR41) 2012; 433 EA Berger (3409_CR5) 1998; 391 P Delobel (3409_CR53) 2005; 38 RI Connor (3409_CR6) 1997; 185 JJ De Jong (3409_CR22) 1992; 66 CD Mathers (3409_CR10) 2006; 3 T Lengauer (3409_CR36) 2007; 25 S Kassaye (3409_CR15) 2009; 50 M Coetzer (3409_CR50) 2011; 56 F Groot (3409_CR7) 2006; 3 A Brelot (3409_CR43) 1999; 73 MR Jakobsen (3409_CR11) 2010; 5 T Cilliers (3409_CR14) 2003; 77 16284180 - Science. 2005 Nov 11;310(5750):1025-8 9440686 - Nature. 1998 Jan 15;391(6664):240 18066037 - Nat Biotechnol. 2007 Dec;25(12):1407-10 16476981 - J Gen Virol. 2006 Mar;87(Pt 3):607-12 16966601 - Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):13950-5 19996764 - J Acquir Immune Defic Syndr. 2010 Feb;53(2):167-75 14671134 - J Virol. 2004 Jan;78(1):524-30 18507530 - AIDS Res Hum Retroviruses. 2008 May;24(5):743-51 22010208 - J Antimicrob Chemother. 2012 Jan;67(1):25-31 12490404 - Virology. 2002 Dec 5;304(1):70-80 20921899 - J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):9-15 19295330 - J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):9-18 12438614 - J Virol. 2002 Dec;76(24):12890-9 16779731 - J Infect Dis. 2006 Jul 15;194(2):238-46 14645592 - J Virol. 2003 Dec;77(24):13376-88 1404617 - J Virol. 1992 Nov;66(11):6777-80 8649511 - Nature. 1996 Jun 20;381(6584):661-6 12634405 - J Virol. 2003 Apr;77(7):4449-56 8649512 - Nature. 1996 Jun 20;381(6584):667-73 15764954 - J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):382-92 20530226 - Antimicrob Agents Chemother. 2010 Aug;54(8):3335-40 11907225 - J Virol. 2002 Apr;76(8):3852-64 8674119 - Cell. 1996 Jun 28;85(7):1135-48 22954962 - Virology. 2012 Nov 25;433(2):296-307 16406460 - Virology. 2006 Apr 10;347(2):247-60 8629022 - Science. 1996 May 10;272(5263):872-7 19695656 - Virology. 2009 Oct 10;393(1):56-67 16942785 - Virology. 2006 Dec 5-20;356(1-2):95-105 11144640 - Infect Dis Clin North Am. 2000 Dec;14(4):809-25, v-vi 18753930 - AIDS. 2008 Sep 12;22(14):F11-6 16378977 - J Virol. 2006 Jan;80(2):750-8 22732432 - Virus Res. 2012 Sep;168(1-2):73-83 18199789 - J Clin Microbiol. 2008 Mar;46(3):887-91 16706624 - AIDS Res Hum Retroviruses. 2006 May;22(5):458-65 22999094 - Virology. 2013 Jan 5;435(1):170-8 16251317 - Antimicrob Agents Chemother. 2005 Nov;49(11):4721-32 10074102 - J Virol. 1999 Apr;73(4):2576-86 21427401 - Clin Infect Dis. 2011 Apr 1;52(7):925-8 17411375 - AIDS Res Hum Retroviruses. 2007 Mar;23(3):415-26 9034141 - J Exp Med. 1997 Feb 17;185(4):621-8 18427209 - AIDS. 2008 Apr 23;22(7):896-9 16641263 - J Virol. 2006 May;80(10):4698-704 21555814 - Antivir Ther. 2011;16(3):319-28 1560543 - J Virol. 1992 May;66(5):3183-7 1409653 - Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9434-8 19249948 - Pharmacotherapy. 2009 Mar;29(3):295-304 16916447 - Retrovirology. 2006;3:52 14990703 - J Virol. 2004 Mar;78(6):2841-52 17132052 - PLoS Med. 2006 Nov;3(11):e442 9261347 - J Virol. 1997 Sep;71(9):6305-14 1905842 - Science. 1991 Jul 5;253(5015):71-4 |
| References_xml | – volume: 66 start-page: 3183 issue: 5 year: 1992 ident: 3409_CR25 publication-title: J Virol doi: 10.1128/jvi.66.5.3183-3187.1992 – volume: 168 start-page: 73 issue: 1–2 year: 2012 ident: 3409_CR29 publication-title: Virus Res doi: 10.1016/j.virusres.2012.06.019 – volume: 52 start-page: 925 issue: 7 year: 2011 ident: 3409_CR20 publication-title: Clin Infect Dis doi: 10.1093/cid/cir072 – volume: 14 start-page: 809 issue: 4 year: 2000 ident: 3409_CR8 publication-title: Infect Dis Clin North Am doi: 10.1016/S0891-5520(05)70135-5 – volume: 80 start-page: 750 issue: 2 year: 2006 ident: 3409_CR51 publication-title: J Virol doi: 10.1128/JVI.80.2.750-758.2006 – volume: 16 start-page: 319 issue: 3 year: 2011 ident: 3409_CR52 publication-title: Antivir Ther doi: 10.3851/IMP1769 – volume: 194 start-page: 238 issue: 2 year: 2006 ident: 3409_CR9 publication-title: J Infect Dis doi: 10.1086/504693 – volume: 3 start-page: 52 year: 2006 ident: 3409_CR7 publication-title: Retrovirology doi: 10.1186/1742-4690-3-52 – volume: 77 start-page: 4449 issue: 7 year: 2003 ident: 3409_CR14 publication-title: J Virol doi: 10.1128/JVI.77.7.4449-4456.2003 – volume: 76 start-page: 12890 issue: 24 year: 2002 ident: 3409_CR34 publication-title: J Virol doi: 10.1128/JVI.76.24.12890-12899.2002 – volume: 77 start-page: 13376 issue: 24 year: 2003 ident: 3409_CR24 publication-title: J Virol doi: 10.1128/JVI.77.24.13376-13388.2003 – volume: 103 start-page: 13950 issue: 38 year: 2006 ident: 3409_CR40 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0606312103 – volume: 87 start-page: 607 issue: Pt 3 year: 2006 ident: 3409_CR48 publication-title: J Gen Virol doi: 10.1099/vir.0.81510-0 – volume: 381 start-page: 661 issue: 6584 year: 1996 ident: 3409_CR1 publication-title: Nature doi: 10.1038/381661a0 – volume: 67 start-page: 25 issue: 1 year: 2012 ident: 3409_CR31 publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkr438 – volume: 304 start-page: 70 issue: 1 year: 2002 ident: 3409_CR47 publication-title: Virology doi: 10.1006/viro.2002.1760 – volume: 393 start-page: 56 issue: 1 year: 2009 ident: 3409_CR32 publication-title: Virology doi: 10.1016/j.virol.2009.07.021 – volume: 25 start-page: 1407 issue: 12 year: 2007 ident: 3409_CR36 publication-title: Nat Biotechnol doi: 10.1038/nbt1371 – volume: 22 start-page: F11 issue: 14 year: 2008 ident: 3409_CR30 publication-title: AIDS doi: 10.1097/QAD.0b013e32830ebcd4 – start-page: 2869 volume-title: Kucers’ The Use of Antibiotics year: 2010 ident: 3409_CR19 doi: 10.1201/b13787-282 – volume: 391 start-page: 240 issue: 6664 year: 1998 ident: 3409_CR5 publication-title: Nature doi: 10.1038/34571 – volume: 29 start-page: 295 issue: 3 year: 2009 ident: 3409_CR18 publication-title: Pharmacotherapy doi: 10.1592/phco.29.3.295 – volume: 433 start-page: 296 issue: 2 year: 2012 ident: 3409_CR41 publication-title: Virology doi: 10.1016/j.virol.2012.08.013 – volume: 356 start-page: 95 issue: 1–2 year: 2006 ident: 3409_CR42 publication-title: Virology doi: 10.1016/j.virol.2006.07.030 – volume: 89 start-page: 9434 issue: 20 year: 1992 ident: 3409_CR38 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.89.20.9434 – volume: 56 start-page: 9 issue: 1 year: 2011 ident: 3409_CR50 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3181f63906 – volume: 310 start-page: 1025 issue: 5750 year: 2005 ident: 3409_CR45 publication-title: Science doi: 10.1126/science.1118398 – volume: 5 start-page: 219 year: 2010 ident: 3409_CR11 publication-title: Futur Virol doi: 10.2217/fvl.09.77 – volume: 76 start-page: 3852 issue: 8 year: 2002 ident: 3409_CR23 publication-title: J Virol doi: 10.1128/JVI.76.8.3852-3864.2002 – volume: 71 start-page: 6305 issue: 9 year: 1997 ident: 3409_CR44 publication-title: J Virol doi: 10.1128/jvi.71.9.6305-6314.1997 – volume: 23 start-page: 415 issue: 3 year: 2007 ident: 3409_CR39 publication-title: AIDS Res Hum Retroviruses doi: 10.1089/aid.2006.0130 – volume: 46 start-page: 887 issue: 3 year: 2008 ident: 3409_CR28 publication-title: J Clin Microbiol doi: 10.1128/JCM.01611-07 – volume: 85 start-page: 1135 issue: 7 year: 1996 ident: 3409_CR4 publication-title: Cell doi: 10.1016/S0092-8674(00)81313-6 – volume: 38 start-page: 382 issue: 4 year: 2005 ident: 3409_CR53 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/01.qai.0000152835.17747.47 – volume: 24 start-page: 743 issue: 5 year: 2008 ident: 3409_CR12 publication-title: AIDS Res Hum Retroviruses doi: 10.1089/aid.2007.0304 – volume: 78 start-page: 524 issue: 1 year: 2004 ident: 3409_CR49 publication-title: J Virol doi: 10.1128/JVI.78.1.524-530.2004 – volume: 22 start-page: 896 issue: 7 year: 2008 ident: 3409_CR13 publication-title: AIDS doi: 10.1097/QAD.0b013e3282f57f7a – volume: 347 start-page: 247 issue: 2 year: 2006 ident: 3409_CR35 publication-title: Virology doi: 10.1016/j.virol.2005.11.047 – volume: 185 start-page: 621 issue: 4 year: 1997 ident: 3409_CR6 publication-title: J Exp Med doi: 10.1084/jem.185.4.621 – volume: 253 start-page: 71 issue: 5015 year: 1991 ident: 3409_CR21 publication-title: Science doi: 10.1126/science.1905842 – volume: 53 start-page: 167 issue: 2 year: 2010 ident: 3409_CR27 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3181c8413b – volume: 272 start-page: 872 issue: 5263 year: 1996 ident: 3409_CR3 publication-title: Science doi: 10.1126/science.272.5263.872 – volume: 49 start-page: 4721 issue: 11 year: 2005 ident: 3409_CR17 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.49.11.4721-4732.2005 – volume: 54 start-page: 3335 issue: 8 year: 2010 ident: 3409_CR26 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00148-10 – volume: 381 start-page: 667 issue: 6584 year: 1996 ident: 3409_CR2 publication-title: Nature doi: 10.1038/381667a0 – volume: 50 start-page: 9 issue: 1 year: 2009 ident: 3409_CR15 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e31818ffdff – volume: 73 start-page: 2576 issue: 4 year: 1999 ident: 3409_CR43 publication-title: J Virol doi: 10.1128/JVI.73.4.2576-2586.1999 – volume: 78 start-page: 2841 issue: 6 year: 2004 ident: 3409_CR46 publication-title: J Virol doi: 10.1128/JVI.78.6.2841-2852.2004 – volume: 435 start-page: 170 issue: 1 year: 2013 ident: 3409_CR16 publication-title: Virology doi: 10.1016/j.virol.2012.08.048 – volume: 66 start-page: 6777 issue: 11 year: 1992 ident: 3409_CR22 publication-title: J Virol doi: 10.1128/jvi.66.11.6777-6780.1992 – volume: 80 start-page: 4698 issue: 10 year: 2006 ident: 3409_CR37 publication-title: J Virol doi: 10.1128/JVI.80.10.4698-4704.2006 – volume: 3 start-page: e442 issue: 11 year: 2006 ident: 3409_CR10 publication-title: PLoS Med doi: 10.1371/journal.pmed.0030442 – volume: 22 start-page: 458 issue: 5 year: 2006 ident: 3409_CR33 publication-title: AIDS Res Hum Retroviruses doi: 10.1089/aid.2006.22.458 – reference: 21427401 - Clin Infect Dis. 2011 Apr 1;52(7):925-8 – reference: 16916447 - Retrovirology. 2006;3:52 – reference: 16779731 - J Infect Dis. 2006 Jul 15;194(2):238-46 – reference: 12490404 - Virology. 2002 Dec 5;304(1):70-80 – reference: 14990703 - J Virol. 2004 Mar;78(6):2841-52 – reference: 19996764 - J Acquir Immune Defic Syndr. 2010 Feb;53(2):167-75 – reference: 1905842 - Science. 1991 Jul 5;253(5015):71-4 – reference: 15764954 - J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):382-92 – reference: 16476981 - J Gen Virol. 2006 Mar;87(Pt 3):607-12 – reference: 19249948 - Pharmacotherapy. 2009 Mar;29(3):295-304 – reference: 14671134 - J Virol. 2004 Jan;78(1):524-30 – reference: 22010208 - J Antimicrob Chemother. 2012 Jan;67(1):25-31 – reference: 8674119 - Cell. 1996 Jun 28;85(7):1135-48 – reference: 10074102 - J Virol. 1999 Apr;73(4):2576-86 – reference: 18066037 - Nat Biotechnol. 2007 Dec;25(12):1407-10 – reference: 16251317 - Antimicrob Agents Chemother. 2005 Nov;49(11):4721-32 – reference: 17132052 - PLoS Med. 2006 Nov;3(11):e442 – reference: 11907225 - J Virol. 2002 Apr;76(8):3852-64 – reference: 1560543 - J Virol. 1992 May;66(5):3183-7 – reference: 19695656 - Virology. 2009 Oct 10;393(1):56-67 – reference: 17411375 - AIDS Res Hum Retroviruses. 2007 Mar;23(3):415-26 – reference: 8649512 - Nature. 1996 Jun 20;381(6584):667-73 – reference: 16942785 - Virology. 2006 Dec 5-20;356(1-2):95-105 – reference: 1404617 - J Virol. 1992 Nov;66(11):6777-80 – reference: 1409653 - Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9434-8 – reference: 16966601 - Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):13950-5 – reference: 20530226 - Antimicrob Agents Chemother. 2010 Aug;54(8):3335-40 – reference: 11144640 - Infect Dis Clin North Am. 2000 Dec;14(4):809-25, v-vi – reference: 12634405 - J Virol. 2003 Apr;77(7):4449-56 – reference: 18427209 - AIDS. 2008 Apr 23;22(7):896-9 – reference: 16284180 - Science. 2005 Nov 11;310(5750):1025-8 – reference: 18199789 - J Clin Microbiol. 2008 Mar;46(3):887-91 – reference: 18753930 - AIDS. 2008 Sep 12;22(14):F11-6 – reference: 9034141 - J Exp Med. 1997 Feb 17;185(4):621-8 – reference: 12438614 - J Virol. 2002 Dec;76(24):12890-9 – reference: 16378977 - J Virol. 2006 Jan;80(2):750-8 – reference: 8649511 - Nature. 1996 Jun 20;381(6584):661-6 – reference: 9440686 - Nature. 1998 Jan 15;391(6664):240 – reference: 16706624 - AIDS Res Hum Retroviruses. 2006 May;22(5):458-65 – reference: 14645592 - J Virol. 2003 Dec;77(24):13376-88 – reference: 8629022 - Science. 1996 May 10;272(5263):872-7 – reference: 22954962 - Virology. 2012 Nov 25;433(2):296-307 – reference: 22999094 - Virology. 2013 Jan 5;435(1):170-8 – reference: 19295330 - J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):9-18 – reference: 16641263 - J Virol. 2006 May;80(10):4698-704 – reference: 18507530 - AIDS Res Hum Retroviruses. 2008 May;24(5):743-51 – reference: 9261347 - J Virol. 1997 Sep;71(9):6305-14 – reference: 21555814 - Antivir Ther. 2011;16(3):319-28 – reference: 22732432 - Virus Res. 2012 Sep;168(1-2):73-83 – reference: 16406460 - Virology. 2006 Apr 10;347(2):247-60 – reference: 20921899 - J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):9-15 |
| SSID | ssj0031808 |
| Score | 2.1550915 |
| Snippet | Background
The majority of HIV-1 subjects worldwide are infected with HIV-1 subtype C (C-HIV). Although C-HIV predominates in developing regions of the world... The majority of HIV-1 subjects worldwide are infected with HIV-1 subtype C (C-HIV). Although C-HIV predominates in developing regions of the world such as... Background The majority of HIV-1 subjects worldwide are infected with HIV-1 subtype C (C-HIV). Although C-HIV predominates in developing regions of the world... Doc number: 24 Abstract Background: The majority of HIV-1 subjects worldwide are infected with HIV-1 subtype C (C-HIV). Although C-HIV predominates in... |
| SourceID | unpaywall pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 24 |
| SubjectTerms | Algorithms Amino acids Analysis Antibodies Antiviral agents Biomedical and Life Sciences Biomedicine Cancer Research Care and treatment Computational Biology - methods Departments Development and progression Entropy Genotype Health aspects HIV (Viruses) HIV Envelope Protein gp120 - genetics HIV infection HIV-1 - genetics HIV-1 - physiology Humans Infections Infectious Diseases Molecular Biology - methods Protein Structure Receptors, HIV - analysis Vaccine Viral Tropism Virology Virology - methods Viruses |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3db9MwED-NTgh4QHwTGMhISLAHb4k_EgcJoVFtKjxUaLBqb5G_wpBK0nUtaP89vjQJ7aTBWxSfI-fufL6zz78DeG1zaTOjBMUHKowXVFmTUK8SHfO8tLFvsi3G6ehEfD6Vp1sw7u7CYFplZxMbQ-1qi3vk-wlP0hQdaPVhdk6xahSernYlNHRbWsG9byDGbsA2Q2SsAWx_PBx_Oe5sc1DgWLUAP4lK94M7zigGiGiNmNhYm65a6LUl6mr6ZH-GegduLauZvvytp9O1ZeroHtxt_UtysFKI-7Dlqwdwc1Vx8vIh-GF9_NWfTzgdkndEk6r-5adk9GlCE3KxNLghS4YEr19iChGZcNLlWhNc7xxB1EvMhKnnZIk5aWQ2x6MeFC_R0--BY4uzn4_g5Ojw23BE20oL1MpcLmimfJnyMpEqtqVQ2kgfWx84pBPnbGxSLkwel1IqnSplgmHgca6EM0YzF2Is_hgGVV35p0CEKpnSymnHclGiA1F6x7SzwT9mNssj2Ot4XNgWhhyrYUyLJhxRaYFCKVAo-IaJCN72HWYrBI7rSd-g0Aqcm-GbVrdXDMLIEOWqOJAciUWeRLCzQRnmlN1s7sRetHP6ovirgRG86puxJ-apVb5eNjSZCh4P4xE8WWlJP2jGQ-gd9D-CbEN_egJE-t5sqX6cNYjfXOZ5xmUEu52mrQ3rOl7s9qr4P749-_fvPofbrCkCghe5dmCwmC_9i-CKLczLdn79Aa-fLtE priority: 102 providerName: ProQuest – databaseName: SpringerLink - Revues - OpenAccess dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR3LbtQw0IIiRDkgniVQkJGQoAeXxK_Y3KoV1cKBA9BVb5FfoZVCsmw3oP49nmwSbSoqxC2Kx5E1D89M5oXQa6eFy63iBB4It4ET5WxGgspMynTp0tBlW3yW8xP-6VSc9k2SoBZmO36fKfkuGsyUgAsH9wXlN9GtqKFkF5WVs-HKjXyZqr5vz182TVTO1Yt3S_NczYocQ6N30Z22XprL36aqtrTP8X10rzcb8dGGzg_QjVA_RLc3gyQvHyE_a758DT8XjMzeY4Pr5leo8PzjgmT4orXwmxXPMBRVQmIQXjA8ZFBj0GIeQy9LyG9pVriFTDO8XEEAB4iGTfW9WZ2vz348RifHH77N5qSfn0Cc0GJNchVKycpMqNSVXBkrQupCRJDJvHeplYxbnZZCKCOVslHcWaoV99Ya6qPnxJ6gnbqpw1OEuSqpMsobTzUvwSwog6fGu2j1UpfrBB0OKC5c31wcZlxURedkKFkATQqgCbyhPEFvxw3LTV-N60HfAM0KkLj4TWf6woF4MuhdVRwJBsBcZwnan0BGSXHT5YHqRS-pF0XGMinBMVMJejUuw07IPqtD03YwuYp2DGUJ2tswyXhoyqJDHbk6QfmEfUYA6N89XanPz7o-3kxonTORoIOB0baOdR0uDkZO_Bfenv3Hd5-jXdrN-YBarX20s1614UW0ttb2ZSdpfwD-Vh9Y priority: 102 providerName: Springer Nature – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR3batRAdNAtoj54rTVaZQRB-5BtMpdk4tuyWFYfiqi71Kcwt9himqxpotSvd06SDbuLRQTfQuZMmDk515lzQeilTriOlWA-PPhMWeYLrULfilAGNMl0YNtoi-NoNmfvT_hJ3w4IcmEqW4MrXbVnyuP1FPS8y3CADgq2OlyarGN4ER06o5r44OaBTCHsOtqJuDPMR2hnfvxh8qVLiewg-uI-f5i1oZe2pfOaetoOnRzuT2-jm02xlJc_ZZ6vqaijuyhfba6LTPk2bmo11r-26j7-p93fQ3d6UxZPOtq7j67Z4gG60TW3vHyIzLT8-Ml-X1B_-gZLXJQ_bI5n7xZ-iC8aBUe_eIoh0ROClfCC4lVUNwbNajDU14SYm7LCDUS_4WUFl0pASFjmX8vqrD4930Xzo7efpzO_7-nga57w2o-FzSKahVwEOmNCKm4Dbd0-ZGiMDlREmUqCjHMhIyGUE0E0SAQzSklinDdHH6FRURb2McJMZERIYaQhCcvAVMmsIdJoZ4kTHSceGq_-aKr7gufQdyNPW8dHRCmgLgXUwRvCPPR6mLDsan1cDfoKSCQFKeC-qWWfzOBWBvW00gmnAMyS0EP7G5COe_Xm8IrI0l56XKQhDaMInEXhoRfDMMyEiLjClk0LEwtnWxHqob2OJodFE-qcfMdpHoo3qHUAgJrimyPF2WlbW5zyJIkp99DBiq7XlnUVLg4Gwv8b3p78A-xTdIu0vUcgf2wfjeqqsc-cBVir5z1n_waVLFQ2 priority: 102 providerName: Unpaywall |
| Title | CoRSeqV3-C: a novel HIV-1 subtype C specific V3 sequence based coreceptor usage prediction algorithm |
| URI | https://link.springer.com/article/10.1186/1742-4690-10-24 https://www.ncbi.nlm.nih.gov/pubmed/23446039 https://www.proquest.com/docview/1316602178 https://www.proquest.com/docview/1317861423 https://pubmed.ncbi.nlm.nih.gov/PMC3599735 https://retrovirology.biomedcentral.com/counter/pdf/10.1186/1742-4690-10-24 |
| UnpaywallVersion | publishedVersion |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1742-4690 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0031808 issn: 1742-4690 databaseCode: RBZ dateStart: 20040101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1742-4690 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0031808 issn: 1742-4690 databaseCode: KQ8 dateStart: 20040201 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1742-4690 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0031808 issn: 1742-4690 databaseCode: KQ8 dateStart: 20040101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1742-4690 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0031808 issn: 1742-4690 databaseCode: DOA dateStart: 20040101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1742-4690 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0031808 issn: 1742-4690 databaseCode: ABDBF dateStart: 20040101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1742-4690 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0031808 issn: 1742-4690 databaseCode: DIK dateStart: 20040101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1742-4690 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0031808 issn: 1742-4690 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1742-4690 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0031808 issn: 1742-4690 databaseCode: M~E dateStart: 20040101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1742-4690 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0031808 issn: 1742-4690 databaseCode: RPM dateStart: 20040101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1742-4690 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0031808 issn: 1742-4690 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1742-4690 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0031808 issn: 1742-4690 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1742-4690 dateEnd: 20250228 omitProxy: true ssIdentifier: ssj0031808 issn: 1742-4690 databaseCode: M48 dateStart: 20040501 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAVX databaseName: Springer Nature HAS Fully OA customDbUrl: eissn: 1742-4690 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0031808 issn: 1742-4690 databaseCode: AAJSJ dateStart: 20041201 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: Springer Nature OA Free Journals customDbUrl: eissn: 1742-4690 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0031808 issn: 1742-4690 databaseCode: C6C dateStart: 20040112 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfYJgQ8IL4JjMpICNiDR2I7iY2EUIk2lUpU00ar7imyHWebFNKPtUD_e3xpGtppEzwlis-Rcx_2XXy-H0JvjAxNrAUncEO4tpwIowNiRaB8JnPj2yrbohd1-rw7DId_oUprBl5eG9oBnlR_Wuz_niw-O4P_VBm8iD44p5oSCPNgTqH87XhCAFUKdl9riI0ttONWLgnQDt94s8vg1LlCrGv616V_rnnnxqp1de5eW7yuJlY2u6v30J15OVaLX6oo1hawwwfofu154vZSVR6iW7Z8hG4vsSgXj1GWjI5P7GTASPIRK1yOftoCd74OSIAv5xr-1OIEw7lMyC3CA4ZXSdgYFsIMQzlMSJEZTfEcktXweAp7QCB3rIozx6rZ-Y8nqH948D3pkBqCgZhQhjMSC5tHLA9C4ZucC6VD6xvrGKSCLDO-jhjX0s_DUKhICO1mDOZLwTOtFc1c8MWeou1yVNrnCHORU6FEpjIqeQ6eRW4zqjLjHGdqYumh_RWLU1PXJweYjCKt4hQRpSCTFGQCTyj30Pumw3hZmuNm0ncgsxTUyL3TqPrsgRsZlL9K2yEDYi4DD-1uUDpjM5vNK6mnK11NAxZEEcR2wkOvm2boCQlspR3NK5pYOFeIMg89WypJM2jKXEzuDMND8Yb6NARQAnyzpbw4r0qBs1DKmIUe2lsp2tqwbuLFXqOJ_-Lbi__4npfoLq0gQuCY1y7ank3n9pVz1Ga6hbbiYdxCO-1296Trrl8OekfH7mkSJa3q50erskfX0u8dtU__AEWjPX8 |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw9GhsQoMHxJ3AACOBYA9hie0kNtKERtnUslGhsVV7C47jMKSQdL0w9ef4NnzSJLSTBk97i-ITy_G52-cC8FLLQEeJ4C4-uDwx3BU68V0jfOUxmWnPVNEW_bB7zD-dBCcr8LvJhcGwykYmVoI6LTWekW_5zA9DNKDF--GZi12j8Ha1aaGh6tYK6XZVYqxO7Ng3s3Prwo23ex8tvl9Rurd71Om6dZcBVwcymLiRMFnIMj8Qns64UElgPG18ESo_TbWXhIwn0suCQKhQiMQyBfOk4GmSKJpa_4LZea_BGmdcWudv7cNu_8thowssw3iiLihkZ9yy5j910SFF6Uf5ki68qBEWVOLFcM32zvYmrE-LoZqdqzxfUIt7t-FWbc-SnTkB3oEVU9yF6_MOl7N7YDrl4VdzNmBuh7wjihTlL5OTbm_g-mQ8TfAAmHQIpntiyBIZMNLEdhPUrynBKpsYeVOOyBRj4MhwhFdLSE5E5d8thianP-_D8ZXs-QNYLcrCPALCRUaFEqlKqeQZGiyZSalKtbXHqY6kA2-bPY51XfYcu2_kceX-iDBGpMSIFHxDuQNv2g-G84ofl4O-RqTFKAvsnFrVKQ12ZVhVK94JGAJz6TuwsQRpeVgvDzdoj2sZMo7_UrwDL9ph_BLj4gpTTiuYSFgLizIHHs6ppF00ZdbVt_zmQLREPy0AVhZfHil-nFYVxlkgZcQCBzYbSltY1mV7sdmS4v_27fG_f_c5rHePPh_EB73-_hO4QasGJJhEtgGrk9HUPLVm4CR5VvMagW9Xzd5_AJ13a5M |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Zb9QwEB5BEdcD4iyBAkZCgj6EJj4Sh7cqsNoCqhDQVd8iX2krLcmyB6j_Hk8u7VZUiLcoHkfWHJ6Z-PMMwCuTCZNqyUN8CLl2PJRGx6GTsYpYVprINWiLw2R8xD8ei-MOm7Po0e79kWR7pwGrNFXLvZktWxOXyZ4Po2mIiR3uIpRfhWvcuzZsYJAneb8Re22NZFfN5y-TNhzRxe14zR9dxEoOB6a34eaqmqnz32o6XfNJo7twpwsmyX4r_XtwxVX34XrbXvL8Adi8_vrN_ZywMH9HFKnqX25KxgeTMCaLlcafryQneNUS4UJkwkiPqybo2yzBCpeIeqnnZIX4MzKb47EOipKo6Uk9P1ue_ngIR6MP3_Nx2HVVCI3IxDJMpSsTVsZCRqbkUmnhIuM8g1RsrYl0wrjOolIIqRIptd8EWJRJbrVW1Pp8ij2Craqu3GMgXJZUKmmVpRkvMVgonaXKGh8LU5NmAbztWVyYruQ4dr6YFk3qIZMCZVKgTPAN5QG8GSbM2mobl5O-RpkVaIf-m0Z11wn8yrCiVbEvGBLzLA5gZ4PS24_ZHO6lXnT2uyhiFicJpmsygJfDMM5ETFrl6lVDk0of3VAWwHarJMOiKfNpttf1ANIN9RkIsKr35kh1dtpU92Yiy1ImAtjtFW1tWZfxYnfQxH_x7cl_fPcF3PjyflR8Pjj89BRu0aYRCF7m2oGt5XzlnvlwbKmfN0b3B6c6Ko4 |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR3batRAdNAtoj54rTVaZQRB-5BtMpdk4tuyWFYfiqi71Kcwt9himqxpotSvd06SDbuLRQTfQuZMmDk515lzQeilTriOlWA-PPhMWeYLrULfilAGNMl0YNtoi-NoNmfvT_hJ3w4IcmEqW4MrXbVnyuP1FPS8y3CADgq2OlyarGN4ER06o5r44OaBTCHsOtqJuDPMR2hnfvxh8qVLiewg-uI-f5i1oZe2pfOaetoOnRzuT2-jm02xlJc_ZZ6vqaijuyhfba6LTPk2bmo11r-26j7-p93fQ3d6UxZPOtq7j67Z4gG60TW3vHyIzLT8-Ml-X1B_-gZLXJQ_bI5n7xZ-iC8aBUe_eIoh0ROClfCC4lVUNwbNajDU14SYm7LCDUS_4WUFl0pASFjmX8vqrD4930Xzo7efpzO_7-nga57w2o-FzSKahVwEOmNCKm4Dbd0-ZGiMDlREmUqCjHMhIyGUE0E0SAQzSklinDdHH6FRURb2McJMZERIYaQhCcvAVMmsIdJoZ4kTHSceGq_-aKr7gufQdyNPW8dHRCmgLgXUwRvCPPR6mLDsan1cDfoKSCQFKeC-qWWfzOBWBvW00gmnAMyS0EP7G5COe_Xm8IrI0l56XKQhDaMInEXhoRfDMMyEiLjClk0LEwtnWxHqob2OJodFE-qcfMdpHoo3qHUAgJrimyPF2WlbW5zyJIkp99DBiq7XlnUVLg4Gwv8b3p78A-xTdIu0vUcgf2wfjeqqsc-cBVir5z1n_waVLFQ2 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CoRSeqV3-C%3A+a+novel+HIV-1+subtype+C+specific+V3+sequence+based+coreceptor+usage+prediction+algorithm&rft.jtitle=Retrovirology&rft.au=Cashin%2C+Kieran&rft.au=Gray%2C+Lachlan+R&rft.au=Jakobsen%2C+Martin+R&rft.au=Sterjovski%2C+Jasminka&rft.date=2013-02-27&rft.issn=1742-4690&rft.eissn=1742-4690&rft.volume=10&rft.spage=24&rft_id=info:doi/10.1186%2F1742-4690-10-24&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1742-4690&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1742-4690&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1742-4690&client=summon |